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clude all accommodations and ancillaries. Cost estimates,
adjusted for medical inflation and cost-to-charge ratios,
are reported in 1998 US$. RESULTS: From 1995 to
1998, the rate of hospital admissions for MA residents
with AIDS declined substantially. In 1995, 86% of the
3,162 AIDS patients were admitted at least once during
the year compared to 31% of the 5,636 patients in 1998.
The mean number of annual admissions per patient
dropped from 2 to 1.76 and the inpatient case fatality
rate fell from 6.7% to 4.6%. The mean LOS per AIDS
admission fell by 1.3 days; a greater decline than the 0.4
day average observed in MA over the same period. The
mean hospital stay cost decreased from $8,070 to
$7,538. These changes accounted for a $2,900 drop in
the mean annual hospitalization cost per AIDS patient
during that time. Discharge to sub-acute inpatient and
home health services fell by 8.6% in this period. All
changes reported are statistically significant (p  0.05).
CONCLUSIONS: The change in LOS is not the result of
post-discharge resource use shifting. The decrease in re-
source use and costs observed after the introduction of
HAART are consistent with an economically beneficial
impact of these agents.
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Although information exists in the form of projected
costs, limited data are available on the overall cost of ill-
ness resulting from varicella-zoster virus (VZV) infection.
VZV is usually a benign childhood illness, but reactiva-
tion of latent VZV can lead to serious complications.
OBJECTIVE: To assess via medical claims the costs asso-
ciated with VZV infection and its resultant complications
from the payers’ perspective. METHODS: We conducted
a retrospective database analysis of 73,869 managed care
members continuously enrolled throughout calendar year
1999. Records of members with a diagnosis code of ei-
ther primary varicella (ICD9-052) or herpes zoster (ICD-
053) were selected. Data was extracted and cost information
was tallied for all medical claims including inpatient hos-
pitalizations, primary care visits, specialist visits, emer-
gency department visits, and specialty procedures. Cost
data are reported in 1999 US dollars. RESULTS: In 1999,
a total of 119 patients were diagnosed with varicella
(52%) and herpes zoster (48%). The mean cost to the
payer was $496.77/patient. The average amount paid out
for members with varicella was $181.87. The average
cost per member with herpes zoster was $786.27. Sixty-
two (52%) VZV afflicted members were diagnosed with
varicella while 57 were diagnosed with herpes zoster. The
amount paid for members over age 19 (n  56) was
$640.30/patient. Of these patients, 14% were classified
with varicella infection, whereas 86% were classified as
having zoster. For members aged 19 (n  63), the mean
amount paid was $369.18/patient. In this group, 78%
were diagnosed with varicella infection, whereas 22%
were diagnosed with zoster. CONCLUSION: The above
costs document for the first time the true cost of VZV in-
fection from the payers’ perspective. Further efforts to
expand vaccination programs should take these costs into
consideration.
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OBJECTIVES: The aim of this analysis is to estimate the
economic impacts of oseltamivir treatment for influenza
in Japan. METHODS: A decision tree with endpoints of
occurrences of pneumonia was constructed to compare
two treatment strategies, oseltamivir treatment and con-
ventional treatment, for otherwise healthy adult (over 16)
patients with influenza like illness in Japan. Drug con-
sumption data (e.g., acetaminophen, antibiotics, and pal-
liative drugs for influenza like illness related symptoms)
were collected prospectively as well as work absenteeism
data as part of the Japanese placebo-controlled double-
blind multicenter study by oseltamivir that included 316
patients. Parameters used in the decision tree were mainly
derived from this study and combined with published
data. Sensitivity analyses were also performed to examine
the robustness of the results. RESULTS: Expected total
medical cost per patient was 14,100 yen and 14,412 yen
for oseltamivir treatment and conventional treatment, re-
spectively. Expected cost including production loss was
56,654 yen and 63,485 yen, for oseltamivir treatment
and conventional treatment, respectively. Based on the
results of basic analyses, the savings that could be ex-
pected in Japanese nationwide health care costs with
widespread use of oseltamivir ranged from 1.1 billion yen to
3.4 billion yen. CONCLUSION: This study suggested that
oseltamivir treatment for patients with flu-like symptoms
can be attractive from the societal perspective in Japan.
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Antibiotic resistance is of growing importance to the Ca-
nadian health care system due to the morbidity, mortal-
ity, and financial costs of certain pathogens for which
there are limited therapeutic options. Among the resistant
organisms, the incidence of methicillin-resistant Staphy-
lococcus species (MRSS) is rising and is posing an in-
creasing burden to health care systems. OBJECTIVE: To
characterize MRSS treatment patterns in patients with
